Retail Clinics

  • FDA approves Orexo’s low-dose Zubsolv

    SILVER SPRING, Md. — The Food and Drug Administration has approved Orexo’s Zubsolv (buprenorphine 0.7 mg/naloxone 0.18 mg) sublingual tablets, the company announced Thursday. The drug is indicated to treat patients with opioid dependence. 
     
    With this approval, Orexo now has FDA approval for six dosage strength tablets: 11.4 mg buprenorphine/2.9 mg naloxone, 8.6 mg/2.1 mg, 5.7 mg/1.5 mg, 2.9 mg/0.71 mg, 1.4 mg/0.36 mg and 0.7 mg/0.18 mg. 
     
  • Health Canada approves Adapt Pharma’s Narcan Nasal Spray

    DUBLIN, Ireland — Health Canada on Tuesday approved naloxone hydrochloride nasal spray, a nasal delivery method for the opioid overdose medication, which Adapt Pharma said it would market as Narcan Nasal Spray. 
     
X
This ad will auto-close in 10 seconds